TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1826920

Group type: EXPERIMENTAL
Intervention: Back school therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spinal manipulative therapy
Number of subjects: 0
Study: 7074980

Group type: EXPERIMENTAL
Intervention: 16 mg naloxone administered to women on days 2‐4 of the puerperium
Number of subjects: 6
Study: 31641322

Group type: EXPERIMENTAL
Intervention: Family-oriented cardiovascular risk reduction interventions
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Study participation
Number of subjects: 11
Study: 29895376

Group type: EXPERIMENTAL
Intervention: 800 mg of elemental calcium as calcium citrate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Calcium chloride (control)
Number of subjects: 27
Study: 26817642

Group type: EXPERIMENTAL
Intervention: Pathogen-reduced platelet concentrates treated by the Mirasol system
Number of subjects: 618

Group type: COMPARATOR
Intervention: Standard plasma-stored platelet concentrates
Number of subjects: 618
Study: 24793078

Group type: EXPERIMENTAL
Intervention: ABH Gel (lorazepam, diphenhydramine, haloperidol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABH Gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABH Gel and Placebo
Number of subjects: 0
Study: 22560128

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 20881623

Group type: EXPERIMENTAL
Intervention: Physical examinations by an occupational medicine physician
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Physical examinations by a physical therapist
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Physical examinations including symptoms for elbow and hand/wrist tests
Number of subjects: 111
Study: 18574656

Group type: EXPERIMENTAL
Intervention: CFPN-PI for 5 days (9-10 mg/kg/day, three times a day)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: CFPN-PI for 10 days (three times a day)
Number of subjects: 250

Group type: COMPARATOR
Intervention: AMPC for 10 days (three times a day)
Number of subjects: 250
Study: 15830233

Group type: EXPERIMENTAL
Intervention: Delta(9)-THC 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Delta(9)-THC 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Delta(9)-THC (10 and 20 mg)
Number of subjects: 10
Study: 11937721

Group type: EXPERIMENTAL
Intervention: 50% sucrose solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 0
Study: 9548151

Group type: EXPERIMENTAL
Intervention: FSH treatment (60 patients)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo treatment (30 patients)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: FSH treatment
Number of subjects: 90
Study: 8160602

Group type: EXPERIMENTAL
Intervention: Amiodarone (400 mg/day)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Mexiletine (720 mg/day)
Number of subjects: 101
Study: 2963532

Group type: EXPERIMENTAL
Intervention: 1 g vitamin E/d
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30587210

Group type: EXPERIMENTAL
Intervention: Field assessment
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Hospital transport
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: ICD code assessment
Number of subjects: 1080
Study: 27096218

Group type: EXPERIMENTAL
Intervention: Talking and Learning for Kindergarten program (Edwards, Rosin, Gross, & Chen, 2013)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Kindness Curriculum (Flook, Goldberg, Pinger, & Davidson, 2014)
Number of subjects: 2
Study: 24401815

Group type: EXPERIMENTAL
Intervention: 0.45 g/d eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: 0.9 g/d eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: 1.8 g/d eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 367
Study: 22632798

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol with nitrous oxide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol with air
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isoflurane with air
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isoflurane with nitrous oxide
Number of subjects: 40
Study: 20571135

Group type: EXPERIMENTAL
Intervention: Bayesian network for error detection
Number of subjects: 200

Group type: COMPARATOR
Intervention: Laboratory experts
Number of subjects: 200
Study: 18191112

Group type: EXPERIMENTAL
Intervention: Citalopram (up to 14 weeks)
Number of subjects: 1809
Study: 15696076

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (100 microg twice daily)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Montelukast (5-10 mg nightly depending on age)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Neither medication
Number of subjects: 126
Study: 14521805

Group type: EXPERIMENTAL
Intervention: Weekly doses of cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of 5‐fluorouracil and cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsurgical preoperative staging with positron emission tomography and sentinel lymph node evaluation
Number of subjects: 0
Study: 10231100

Group type: EXPERIMENTAL
Intervention: Ketoprofen 200 mg once daily for 6 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 8542158

Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoid (budesonide 800 micrograms twice daily for 3 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 11
Study: 1468295

Group type: EXPERIMENTAL
Intervention: Premixed insulins
Number of subjects: 64

Group type: COMPARATOR
Intervention: Extemporarily mixed insulins
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: In vitro skills test for insulin preparation
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Blood glucose profiles and HbA1c
Number of subjects: 64
Study: 6398781

Group type: EXPERIMENTAL
Intervention: Urokinase: 800,000 CTA units/day for three days followed by oral anticoagulants
Number of subjects: 29

Group type: COMPARATOR
Intervention: Heparin: mean daily dose 30,000 units for seven days followed by oral anticoagulants
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Urokinase: 3,300,000 CTA units in 12 hours followed by oral anticoagulants
Number of subjects: 29
Study: 30758694

Group type: EXPERIMENTAL
Intervention: 3D convolutional neural networks applied to CTA-SI
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cerebral hemispheric comparison as an input feature
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non-contrast computed tomography (NCCT) as an input feature
Number of subjects: 60
Study: 29084828

Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing chemotherapy
Number of subjects: 283

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: DpR (deepness of response)
Number of subjects: 283
Study: 27002706

Group type: EXPERIMENTAL
Intervention: Complex Training (CT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Block Training (BT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both CT and BT
Number of subjects: 18
Study: 24705587

Group type: EXPERIMENTAL
Intervention: Plasma PTX3 levels in cases with recurrent coronary events
Number of subjects: 4159

Group type: COMPARATOR
Intervention: Plasma PTX3 levels in controls
Number of subjects: 4159

Group type: EXPERIMENTAL
Intervention: Low plasma PTX3 levels
Number of subjects: 4159

Group type: EXPERIMENTAL
Intervention: PTX3 levels
Number of subjects: 4159
Study: 21883507

Group type: EXPERIMENTAL
Intervention: CIDR‐Ovsynch
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: CIDR, DIB, MAP with GnRH analogues
Number of subjects: 402

Group type: COMPARATOR
Intervention: Overall treatment
Number of subjects: 402
Study: 19892837

Group type: EXPERIMENTAL
Intervention: exendin(9-39) amide (300 pmol/kg x min iv)
Number of subjects: 10
Study: 17265529

Group type: EXPERIMENTAL
Intervention: 50 mg dl alpha‐tocopheryl acetate
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: 20 mg beta‐carotene
Number of subjects: 29133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29133
Study: 15638899

Group type: EXPERIMENTAL
Intervention: Transurethral incision of the prostate (TUIP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Suprapubic transvesical prostatectomy (TP)
Number of subjects: 80
Study: 12803676

Group type: EXPERIMENTAL
Intervention: Interferon beta
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins (HMG CoA inhibitors)
Number of subjects: 0
Study: 10599838

Group type: EXPERIMENTAL
Intervention: Kanji writing
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Kana writing
Number of subjects: 8
Study: 7777738

Group type: EXPERIMENTAL
Intervention: Postal questionnaire dispatched on Thursday
Number of subjects: 460

Group type: COMPARATOR
Intervention: Postal questionnaire dispatched on Saturday
Number of subjects: 460
Study: 2339202

Group type: EXPERIMENTAL
Intervention: ONO‐3708 (thromboxane A2 antagonist) administered at a dose of 2 micrograms/kg/min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7422258

Group type: EXPERIMENTAL
Intervention: Anterior vitrectomy
Number of subjects: 13
Study: 31146778

Group type: EXPERIMENTAL
Intervention: Phased award funding mechanism for trial planning and implementation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oversight and management strategies provided by the coordinating center
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Documentation submitted for review by program officers/project scientists
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Phased award mechanism advantages
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Systematic approaches to identify milestones and track metrics
Number of subjects: 6
Study: 28779930

Group type: EXPERIMENTAL
Intervention: Whole body vibration therapy (WBV) combined with 6 different types of exercises at 30 hz frequency, 2 mm amplitude for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group performing the same exercises without vibration
Number of subjects: 20
Study: 26402073

Group type: EXPERIMENTAL
Intervention: FCSRT-FR (free recall of the free and cued selective reminding test)
Number of subjects: 913

Group type: EXPERIMENTAL
Intervention: FCSRT-TR (free and cued recall of the free and cued selective reminding test)
Number of subjects: 913

Group type: COMPARATOR
Intervention: Comparison of FCSRT-FR with MMSE, CDRsb, and CVF ROCs
Number of subjects: 913
Study: 23392473

Group type: EXPERIMENTAL
Intervention: Asymmetric force demands with perceptually split targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symmetric force demands with a perceptually unified target
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Practice interrupted by unimanual or different bimanual conditions
Number of subjects: 0
Study: 21722098

Group type: EXPERIMENTAL
Intervention: High-volume (26 ml) ropivacaine 1% with epinephrine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 48
Study: 18504606

Group type: EXPERIMENTAL
Intervention: Tones spaced an octave apart
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Tones separated by a major seventh
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Tones separated by a minor ninth
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Tones separated by a major ninth
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Tones separated by a minor tenth
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Tones lasting 500 ms
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Tones lasting 200 ms
Number of subjects: 74
Study: 16385193

Group type: EXPERIMENTAL
Intervention: Real-life practice studies (e.g., Triumph project, Quadraet study, ALF-ONE study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study: 15244498

Group type: EXPERIMENTAL
Intervention: Aciclovir 800 mg + MMF 1 g
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Valaciclovir 2 g + MMF 1 g
Number of subjects: 15

Group type: COMPARATOR
Intervention: Valaciclovir 2 g alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Aciclovir 800 mg alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: MMF 1 g alone
Number of subjects: 15
Study: 11423451

Group type: EXPERIMENTAL
Intervention: Peribulbar anaesthesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Retrobulbar anaesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 9251949

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (1 g ampicillin plus 0.5 g sulbactam)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Cefotetan (1 g cefotetan)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam
Number of subjects: 170

Group type: COMPARATOR
Intervention: Cefotetan
Number of subjects: 170
Study: 8489308

Group type: EXPERIMENTAL
Intervention: Operative drainage of the main pancreatic duct (MPD)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Operative treatment in randomized trial
Number of subjects: 143

Group type: COMPARATOR
Intervention: Non-operative treatment in randomized trial
Number of subjects: 143
Study: 3819810

Group type: EXPERIMENTAL
Intervention: Brachytherapy (BRT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Non-BRT
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Adjuvant Adriamycin
Number of subjects: 105
Study: 28414546

Group type: EXPERIMENTAL
Intervention: Infant Behavior Program (IBP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 27296661

Group type: EXPERIMENTAL
Intervention: Innovative combination of formal and peer education followed by FibroScan
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 52
Study: 24914779

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg twice daily for 5 days
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 22453769

Group type: EXPERIMENTAL
Intervention: Ixmyelocel-T
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 19821938

Group type: EXPERIMENTAL
Intervention: AV delay determined by electrogram-based SmartDelay
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: AV delay determined by echocardiography (mitral inflow)
Number of subjects: 950

Group type: COMPARATOR
Intervention: Fixed AV delay (120 ms)
Number of subjects: 950
Study: 18390085

Group type: EXPERIMENTAL
Intervention: Dinoprostone vaginal insert (10 mg) administered for 12 hours without oxytocin (group I)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Dinoprostone vaginal insert (10 mg) with oxytocin (group II)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microg) with oxytocin (group III)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as no treatment)
Number of subjects: 106
Study: 16630553

Group type: EXPERIMENTAL
Intervention: Random cohort with LPL gene mutations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient cohort with LPL P207L deficiency
Number of subjects: 0
Study: 15012730

Group type: EXPERIMENTAL
Intervention: 1‐deamino‐8‐D‐arginine vasopressin (dDAVP) administration
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Water loading and water deprivation
Number of subjects: 14
Study: 11023260

Group type: EXPERIMENTAL
Intervention: Mandibular implant‐supported overdentures
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 102
Study: 8993091

Group type: EXPERIMENTAL
Intervention: Addition of sertraline to ongoing treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Risperidone augmentation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Clomipramine dose increase
Number of subjects: 33
Study: 1447653

Group type: EXPERIMENTAL
Intervention: Odorant identification test using five selected odorants (baby powder, bubble gum, candy cane, fish, orange)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Odorant identification test
Number of subjects: 175
Study: 6546829

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 48
Study: 30834850

Group type: EXPERIMENTAL
Intervention: Table (nutrition table with information on energy and main nutrients per 100 g)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Label (healthy choice label for the healthier product)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Combined (nutrition table and healthy choice label)
Number of subjects: 780

Group type: COMPARATOR
Intervention: Control (picture of the FOP presented)
Number of subjects: 780
Study: 30096878

Group type: EXPERIMENTAL
Intervention: 600 g/day blackberries (BB, 1500 mg/day flavonoids)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Calorie and carbohydrate matched amount of gelatin (GEL, flavonoid-free control)
Number of subjects: 27
Study: 26808688

Group type: COMPARATOR
Intervention: Escitalopram 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Escitalopram 20 mg
Number of subjects: 0
Study: 25461786

Group type: EXPERIMENTAL
Intervention: Student Bodies™+ (SB+) intervention
Number of subjects: 126

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 126
Study: 21887804

Group type: EXPERIMENTAL
Intervention: Fufang Danshen capsule 1000 mg twice-daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 55
Study: 19020291

Group type: EXPERIMENTAL
Intervention: Caffeine (9 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Quercetin (2,000 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18021136

Group type: EXPERIMENTAL
Intervention: APN-provided prenatal care
Number of subjects: 85

Group type: COMPARATOR
Intervention: Physician-provided prenatal care (control)
Number of subjects: 85
Study: 14756855

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg or 50 mg daily for 10 days, starting 5 days before menstrual flow.
Number of subjects: 14
Study: 11191041

Group type: EXPERIMENTAL
Intervention: Group drumming
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control (resting and listening)
Number of subjects: 111
Study: 9990419

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tretinoin 0.025% gel
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tretinoin 0.05% cream
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tretinoin 0.1% cream
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tretinoin 0.01% gel
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tretinoin 0.025% cream
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tretinoin 0.1% gel microsphere
Number of subjects: 55

Group type: COMPARATOR
Intervention: Petrolatum (control)
Number of subjects: 55
Study: 8071051

Group type: EXPERIMENTAL
Intervention: 150 mg I/mL iopromide
Number of subjects: 150

Group type: COMPARATOR
Intervention: 160 mg I/mL ioversol
Number of subjects: 150

Group type: COMPARATOR
Intervention: 128 mg I/mL iopamidol
Number of subjects: 150
Study: 3068828

Group type: EXPERIMENTAL
Intervention: Gelatine-impregnated double-velours grafts
Number of subjects: 224

Group type: COMPARATOR
Intervention: Non-gelatine-impregnated double-velours grafts
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Gelatine-impregnated grafts without velours trimming (Cooley II, Meadox)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Non-gelatine-impregnated grafts without velours trimming (Cooley II, Meadox)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Gelatine-impregnated grafts manufactured by a new warp-knitting procedure (Protegraft 2000, B. Braun AG)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Non-gelatine-impregnated grafts manufactured by a new warp-knitting procedure (Protegraft 2000, B. Braun AG)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Gelatine-impregnated grafts (B. Braun AG)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Non-gelatine-impregnated grafts (B. Braun AG)
Number of subjects: 224
Study: 30064815

Group type: EXPERIMENTAL
Intervention: Dual X-ray absorptiometry body composition data
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 123
Study: 28758822

Group type: EXPERIMENTAL
Intervention: Individually tailored nurse navigation intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 25468459

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Pringle maneuver (PM)
Number of subjects: 160
Study: 22999066

Group type: EXPERIMENTAL
Intervention: Red wine (30 g alcohol/d)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Gin (30 g alcohol/d)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 67
Study: 22185253

Group type: EXPERIMENTAL
Intervention: Fränkel-2 (FR-2) appliance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 0
Study: 19287043

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 3 triplicate predose ECGs
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 1 triplicate predose ECG
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Day ‐1 time‐matched baseline ECGs
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: No baseline correction
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 16705560

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing counseling session
Number of subjects: 131